Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2015 2
2016 1
2017 5
2018 3
2019 6
2020 8
2021 6
2022 4
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia.
Peschke JC, Bergmann R, Mehnert M, Gonzalez Soto KE, Loureiro LR, Mitwasi N, Kegler A, Altmann H, Wobus M, Máthé D, Szigeti K, Feldmann A, Bornhäuser M, Bachmann M, Fasslrinner F, Arndt C. Peschke JC, et al. Among authors: kegler a. Br J Haematol. 2023 Sep;202(6):1137-1150. doi: 10.1111/bjh.18971. Epub 2023 Jul 17. Br J Haematol. 2023. PMID: 37460273
Targeting colorectal cancer cells using AND-gated adaptor RevCAR T-cells.
Soto KEG, Loureiro LR, Bartsch T, Arndt C, Kegler A, Mitwasi N, Drewitz L, Hoffmann L, Saleh HA, Crespo E, Mehnert M, Daglar C, Abken H, Momburg F, Bachmann M, Feldmann A. Soto KEG, et al. Among authors: kegler a. Front Immunol. 2023 Dec 15;14:1302354. doi: 10.3389/fimmu.2023.1302354. eCollection 2023. Front Immunol. 2023. PMID: 38169746 Free PMC article.
RevCAR-expressing immune effector cells for targeting of Fn14-positive glioblastoma.
Saleh HA, Mitwasi N, R Loureiro L, Kegler A, Soto KEG, Hoffmann L, Crespo E, Arndt C, Bergmann R, Bachmann M, Feldmann A. Saleh HA, et al. Among authors: kegler a. Cancer Gene Ther. 2024 Sep;31(9):1323-1334. doi: 10.1038/s41417-024-00766-8. Epub 2024 Apr 6. Cancer Gene Ther. 2024. PMID: 38582787 Free PMC article.
Immunotheranostic target modules for imaging and navigation of UniCAR T-cells to strike FAP-expressing cells and the tumor microenvironment.
Loureiro LR, Hoffmann L, Neuber C, Rupp L, Arndt C, Kegler A, Kubeil M, Hagemeyer CE, Stephan H, Schmitz M, Feldmann A, Bachmann M. Loureiro LR, et al. Among authors: kegler a. J Exp Clin Cancer Res. 2023 Dec 15;42(1):341. doi: 10.1186/s13046-023-02912-w. J Exp Clin Cancer Res. 2023. PMID: 38102692 Free PMC article.
Development and Functional Characterization of a Versatile Radio-/Immunotheranostic Tool for Prostate Cancer Management.
Arndt C, Bergmann R, Striese F, Merkel K, Máthé D, Loureiro LR, Mitwasi N, Kegler A, Fasslrinner F, González Soto KE, Neuber C, Berndt N, Kovács N, Szöllősi D, Hegedűs N, Tóth G, Emmermann JP, Harikumar KB, Kovacs T, Bachmann M, Feldmann A. Arndt C, et al. Among authors: kegler a. Cancers (Basel). 2022 Apr 14;14(8):1996. doi: 10.3390/cancers14081996. Cancers (Basel). 2022. PMID: 35454902 Free PMC article.
Impedimetric Nanobiosensor for the Detection of SARS-CoV-2 Antigens and Antibodies.
Sandoval Bojórquez DI, Janićijević Ž, Palestina Romero B, Oliveros Mata ES, Laube M, Feldmann A, Kegler A, Drewitz L, Fowley C, Pietzsch J, Fassbender J, Tonn T, Bachmann M, Baraban L. Sandoval Bojórquez DI, et al. Among authors: kegler a. ACS Sens. 2023 Feb 24;8(2):576-586. doi: 10.1021/acssensors.2c01686. Epub 2023 Feb 10. ACS Sens. 2023. PMID: 36763494 Free PMC article.
Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells.
Saleh HA, Mitwasi N, Ullrich M, Kubeil M, Toussaint M, Deuther-Conrad W, Neuber C, Arndt C, R Loureiro L, Kegler A, González Soto KE, Belter B, Rössig C, Pietzsch J, Frenz M, Bachmann M, Feldmann A. Saleh HA, et al. Among authors: kegler a. Front Immunol. 2023 Apr 14;14:1166169. doi: 10.3389/fimmu.2023.1166169. eCollection 2023. Front Immunol. 2023. PMID: 37122703 Free PMC article.
A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells.
Kegler A, Drewitz L, Arndt C, Daglar C, Rodrigues Loureiro L, Mitwasi N, Neuber C, González Soto KE, Bartsch T, Baraban L, Ziehr H, Heine M, Nieter A, Moreira-Soto A, Kühne A, Drexler JF, Seliger B, Laube M, Máthé D, Pályi B, Hajdrik P, Forgách L, Kis Z, Szigeti K, Bergmann R, Feldmann A, Bachmann M. Kegler A, et al. Front Immunol. 2023 Jun 13;14:1204543. doi: 10.3389/fimmu.2023.1204543. eCollection 2023. Front Immunol. 2023. PMID: 37383226 Free PMC article.
43 results